The Scientist

» patent and disease/medicine

Most Recent

image: Contributors

Contributors

By | January 1, 2017

Meet some of the people featured in the January 2017 issue of The Scientist.

0 Comments

image: Pharma Redo

Pharma Redo

By | January 1, 2017

Steve Braun of Cures Within Reach, a nonprofit focused on breathing new life into old medicines, describes the potential benefits of drug repurposing.

1 Comment

image: Repurposing Existing Drugs for New Indications

Repurposing Existing Drugs for New Indications

By | January 1, 2017

An entire industry has sprung up around resurrecting failed drugs and recycling existing compounds for novel indications.

1 Comment

image: Infographic: Repurposing Strategies

Infographic: Repurposing Strategies

By | January 1, 2017

Novel uses for existing and failed drugs may save companies time and money in bringing new therapeutics to market.

0 Comments

image: Life Science Controversies of 2016

Life Science Controversies of 2016

By , , and | December 23, 2016

This year, the developers of CRISPR gene-editing technology argued over patent rights, a researcher fought to unmask anonymous PubPeer commenters, US regulators considered “three-parent” babies, and troubles continued for Theranos.

0 Comments

Oncologists have raised concerns about a mouse study that suggests the vaccine for human papillomavirus could cause brain damage.

0 Comments

image: Video: Patent Battle Over CRISPR Gene Editing

Video: Patent Battle Over CRISPR Gene Editing

By | December 13, 2016

The Scientist goes to court for a CRISPR patent interference case at the US Patent and Trademark Office.

0 Comments

image: New Developments in CRISPR Patent Case

New Developments in CRISPR Patent Case

By | December 12, 2016

Documents suggest Feng Zhang started working on CRISPR before Jennifer Doudna’s group published; researchers call for CRISPR technology to be shared openly

0 Comments

image: CRISPR Oral Arguments Recap, Cont’d

CRISPR Oral Arguments Recap, Cont’d

By | December 8, 2016

This week’s CRISPR patent hearing took a deep dive into the science of moving the gene-editing technology from prokaryotes to eukaryotic systems.

2 Comments

image: USPTO to Hear Arguments on CRISPR Patents

USPTO to Hear Arguments on CRISPR Patents

By | December 5, 2016

Tuesday morning, the US Patent and Trademark Office will hear oral arguments from the two parties that claim to have been the first to use CRISPR-Cas9 gene editing technology in eukaryotic cells.

0 Comments

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Streakers, Poopers, and Performers: The Wilder Side of Wildlife Cameras
AAAS